Keloid
Conditions
Interventions
Keloid observation group:None
Sponsors
The First Affiliated Hospital of Xiamen University
Eligibility
Sex/Gender
All
Age
16 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Confirmed as keloid by dermoscopy or pathology; 2. The lesion persists for at least 1 year without any tendency to spontaneously regress; 3. Flat type or crab-foot swelling type, with a minimum diameter of >= 5mm, allowing for 3mm ring biopsy; 4. Planned for surgical resection (removal of excess skin or lipoma, or removal of excess normal tissue can also be used as a normal control); 5. 16–60 years old; 6. Voluntarily signed written informed consent and able to cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1. Within 1-5 years, has received any anti-scar treatment such as radiotherapy, local hormone injection, laser therapy, cryotherapy, etc.; 2. Local complications (lesion rupture, infection, suppuration or suspected malignancy); infection related to immunity (active HIV, HBV, HCV infection; positive PPD; severe infection in the past 3 months; insufficient 8 weeks of live vaccine administration; long-term use of glucocorticoids or other immunosuppressants); 3. Extreme values of body weight or metabolism (BMI 40 kg/m^2; weight loss >= 15 pounds in the past 6 months; uncontrolled hypertriglyceridemia); 4. Impaired function of important organs (ALT/AST > 1.5 times the upper limit of normal, total bilirubin > 1.5 times the upper limit (except Gilbert's syndrome); elevated INR; hemoglobin < 10 g/dL, platelet < 75–150 ×10^9/L, neutrophils < 1.5 ×10^9/L); 5. Non-compliance or cognitive impairment (alcoholism, drug abuse, severe mental illness, dementia, impaired cognitive function; inability to sign informed consent or complete questionnaires/follow-up); 6. Pregnancy, lactation and reproductive planning (pregnant or lactating women; men and women of childbearing age who do not want to use highly effective contraception during the trial); 7. Any situation judged by the researcher as not suitable for participating in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cellular Metabolic Activity;Mitochondrial Functional Status; | — |
Countries
China
Contacts
Public ContactZhang Qiguo
The First Affiliated Hospital of Xiamen University
Outcome results
None listed